Personalized Kidney Screening Could Reduce Type 1 Diabetes Costs

November 2, 2022 by Dan McCue
Personalized Kidney Screening Could Reduce Type 1 Diabetes Costs
(National Institute of Diabetes and Digestive and Kidney Diseases photo)

WASHINGTON — Taking a personalized approach to kidney disease screening for people with type 1 diabetes may reduce the time chronic kidney disease goes undetected and reduce the cost of treatment, according to a new study.

The new analysis, which was performed by the Epidemiology of Diabetes Interventions and Complications study group, was published in the journal Diabetes Care.

According to the study, current chronic kidney disease screening recommendations typically include annual urinary albumin excretion rate testing for anyone who has had T1D for at least five years. 

Albumin is a protein found in the blood and having too much albumin in the urine is a sign of kidney disease. 

The new findings, however, suggest that albumin excretion rate screening could be personalized to optimize testing frequency and early detection of chronic kidney disease.  

Specifically, the researchers suggest, people with T1D who are at low risk of developing chronic kidney disease could be tested for albumin excretion rate less frequently to reduce burden and cost, and those at high risk for chronic kidney disease could be tested more frequently to facilitate earlier detection.

People with T1D have an estimated 50% risk of developing chronic kidney disease over their lifetime. Chronic kidney disease can progress to kidney failure, requiring dialysis or a kidney transplant. 

Using more than 30 years of participant data of albumin excretion rate testing and HbA1c (an integrated measure of blood glucose) from 1,334 participants in the NIDDK-funded Diabetes Control and Complications Trial and the observational follow-up Epidemiology of Diabetes Interventions and Complications study, the study group identified three levels of chronic kidney disease risk that were associated with a later diagnosis. 

They then developed a model to estimate the optimal screening intervals for people with T1D to detect chronic kidney disease at its earliest stages.

According to the model’s findings, people with albumin excretion rate of 21-30 mg per 24 hours and a HbA1c of at least 9% are at high risk for developing chronic kidney disease and could be screened for urine albumin every six months. 

This screening frequency could reduce time with undetected kidney disease so that appropriate interventions can be instituted as early as possible.

Those with albumin excretion rate ≤ 10 mg per 24 hours and a HbA1c ≤ 8% are at lower risk for developing chronic kidney disease and could be screened every two years. This change reduces patient burden and potentially saves millions of dollars compared to annual screening.

All others with T1D ≥ 5 years could continue to be screened annually.

The DCCT, which took place from 1983 to 1993, found that, for people with T1D, keeping blood glucose levels close to normal greatly reduced the chances of developing eye, kidney and nerve disease. Its follow-up study, EDIC, began in 1994 to explore how diabetes affects the body over time and the long-term benefits of early and intensive blood glucose control in the development of later diabetes complications.

The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases, which is part of the National Institutes of Health.

Dan can be reached at [email protected] and at https://twitter.com/DanMcCue.

A+
a-
  • kidney screening
  • Type 1 Diabetes
  • In The News

    Health

    Voting

    Health

    March 27, 2024
    by Dan McCue
    One-Time Treatment Could Revitalize Immune Systems in the Elderly

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of... Read More

    PALO ALTO, Calif. — A new study suggests that a one-time treatment that modulates the composition of a type of immune cell could potentially revitalize the immune systems of the elderly, helping their bodies better react to viral and bacterial threats. The research was carried out... Read More

    March 27, 2024
    by Dan McCue
    Insurers to Expand Access to ‘Navigation Services’ for Cancer Patients

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients... Read More

    WASHINGTON — Seven of the nation’s largest health insurance companies are expanding access to so-called “navigation services” to help patients and their families navigate the myriad challenges that might arise during treatment for cancer and other serious illnesses. The insurers involved are Aetna; Blue Cross Blue... Read More

    Five Takeaways From the Abortion Pill Case Before US Supreme Court

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone,... Read More

    WASHINGTON (AP) — U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone, in a case that could have far-reaching implications for millions of American women and for scores of drugs regulated by the Food and Drug Administration. It's... Read More

    Biden and Harris Argue Democrats Will Preserve Health Care and Republicans Would Take It Away

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in... Read More

    RALEIGH, N.C. (AP) — President Joe Biden and Vice President Kamala Harris on Tuesday promoted their health care agenda in the battleground state of North Carolina, arguing that Democrats like themselves would preserve access to care while Republicans would reverse gains made over the past decade... Read More

    March 26, 2024
    by Tom Ramstack
    Supreme Court Skeptical of Ban on Abortion Pill Mifepristone

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access... Read More

    WASHINGTON — A hearing Tuesday before the Supreme Court indicated a majority of the justices want to maintain women’s access to the abortion pill mifepristone despite objections from anti-abortion activists. The doctors and organizations who sued argued the Food and Drug Administration was wrong in granting... Read More

    March 26, 2024
    by Dan McCue
    Consumers Warned to Avoid Certain Topical Pain Relief Products 

    WASHINGTON — The Food and Drug Administration warned consumers on Tuesday not to use certain over-the-counter pain relief products marketed... Read More

    WASHINGTON — The Food and Drug Administration warned consumers on Tuesday not to use certain over-the-counter pain relief products marketed for topical use before, during or after certain cosmetic procedures. The warning came after the agency issued warning letters to six companies for marketing these products... Read More

    News From The Well
    scroll top